Myelodysplastic Syndrome

	11/05/2009	Conventional Cytogenetics Usually Adequate Way to Test for Primary Myelodysplastic Syndrome: Presented at ASCP - (DGDispatch)
	09/17/2009	Anaemic Patients With MDS Benefit From Erythropoietin, Myeloid Growth Factor Hormones - (DGNews)
	06/08/2009	Hypomethylating Agents Show Better Efficacy Than Best Supportive Care in Patients With Myelodysplastic Syndrome: Presented at EHA - (DGDispatch)
	06/01/2009	Mutation in TET2 in myeloid cancers (N Engl J Med)
	12/24/2008	Azacitidine Approved in EU for Myelodysplastic Syndromes, AML - (DGNews)
	12/08/2008	Decitabine Improves Progression-Free Survival Compared With Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome: Presented at ASH - (DGDispatch)
	08/22/2008	FDA Approves Romiplostim to Treat Chronic Immune Thrombocytopenic Purpura - (DGNews)
	06/15/2008	Data Support Azacytidine as First-Line Therapy for Patients With High-Risk MDS: Presented at EHA - (DGDispatch)
	12/24/2007	Scoring System Identifies MDS Patients Who Have Low-Risk Disease But Poor Prognosis - (DGNews)
	12/13/2007	Azacitidine Prolongs Survival in Patients With High-Risk Myelodysplastic Syndromes: Presented at ASH - (DGDispatch)
	12/12/2007	Cord Blood Enables Stem Cell Transplant in Older Patients Without Matched Related Donors: Presented at ASH - (DGDispatch)
	12/12/2007	Immunotherapy Prolongs Survival in Some Leukemia and MDS Patients: Presented at ASH - (DGDispatch)
	12/10/2007	Deferasirox Retains Long-Term Efficacy in Iron Overload: Presented at ASH - (DGDispatch)
	06/12/2007	Rigorous Strategy for Managing Haematological Events Helps Optimise Lenalidomide Treatment: Presented at EHA - (DGDispatch)
	06/07/2007	Oral HDAC Inhibitor in Combination With Azacitadine Shows Potential in Myelodysplastic Syndrome and Acute Myelogenous Leukaemia: Presented at ASCO - (DGDispatch)
	06/04/2007	Eculizumab Does Not Increase Risk of Leukaemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders: Presented at ASCO - (DGDispatch)
	05/29/2007	Lenalidomide Does Not Appear to Induce Progression of Myelodysplastic Syndrome, But Has Adverse Events: Presented at MDS - (DGDispatch)
	05/24/2007	Comorbidity Analysis Offers New Prognostic Information in Myelodysplastic Syndrome: Presented at MDS - (DGDispatch)
	05/23/2007	Therapies for Myelodysplastic Syndrome Only Improve Survival in Distinct Patient Subgroups: Presented at MDS - (DGDispatch)
	05/22/2007	Gemtuzumab Ozogamicin Boosts Effects of Arsenic Trioxide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukaemia: Presented at MDS - (DGDispatch)
	05/22/2007	Karyotype in Myelodysplastic Syndrome Does Not Influence Efficacy of Azacitidine: Presented at MDS - (DGDispatch)
	05/22/2007	Azacitidine Effective for Myelodysplastic Syndrome in French Trial: Presented at MDS - (DGDispatch)
	05/22/2007	Thalidomide Provides a Durable Response and Survival Benefit Primarily in Patients With Low-Risk Myelodysplastic Disease: Presented at MDS - (DGDispatch)
	05/18/2007	Telomere Loss Associated With Autologous Stem Cell Transplantation May Predict Development of Myelodysplastic Syndrome: Presented at MDS - (DGDispatch)
	01/29/2007	Pharmion Corporation Announces FDA Approval of Vidaza NDA Supplement for IV Administration - (DGNews)
	12/14/2006	Research on Myelodysplastic Syndrome Shows Long Term Benefits for Non Deletion 5q Patients Treated With Lenalidomide - (DGNews)
	12/13/2006	Darbepoetin Alfa Increases Hemoglobin in Myelodysplastic Syndrome: Presented at ASH - (DGDispatch)
	12/13/2006	Different Dosing Schedules of Azacitidine Allow for Transfusion Independence: Presented at ASH - (DGDispatch)
	12/12/2006	Iron Chelation for Myelodysplastic Syndromes Improves Survival Rate: Presented at ASH - (DGDispatch)
	12/11/2006	After Two Years, Study Continues to Show Patients Treated With Revlimid(R) Are Living Longer and Remaining Transfusion Independent - (DGNews)